Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AMY109 plus atezolizumab in advanced solid tumors
jRCT2080225101Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-IL-8 monoclonal antibody in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs) and Safety and tolerability. Started Feb 2020; status: completed.
02
Drugs
anti-IL-8 monoclonal antibody
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080225101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225101.